Your session is about to expire
← Back to Search
Particle Tracers
89Zr-cRGDY Tracer for Brain Cancer
Phase 1
Waitlist Available
Led By Nelson Moss, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Histologically confirmed diagnosis of malignant primary brain tumor clinical and radiographic findings consistent with a pituitary adenoma, or known metastatic cancer with brain lesion presumed to be metastatic
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial is testing if a new type of PET scan can take pictures of brain tumors. The scan uses 89Zr-DFO-cRGDY-PEG-Cy5-C' dot particles, which have only been tested on animals before. The amount of particles given in this study is very small.
Who is the study for?
This trial is for adults over 18 with confirmed malignant brain tumors, pituitary adenomas, or brain metastases from known cancers. Participants must use birth control if of childbearing age and have normal heart function. Pregnant or breastfeeding individuals, those with multiple active cancers, severe claustrophobia, or weight over 400 lbs cannot join.Check my eligibility
What is being tested?
The study tests a new PET scan tracer called 89Zr-DFO-cRGDY-PEG-Cy5-C' dots to see how well it can image brain tumors and track its distribution and removal in the body. This is the first time these particles are used in humans after being tested in mice.See study design
What are the potential side effects?
Since this is the first human test of the tracer, specific side effects are unknown but may include reactions related to PET imaging such as discomfort lying still during scans or allergic reactions to tracers.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I have a confirmed diagnosis of a brain tumor or cancer that has spread to my brain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
distribution within these high-grade gliomas
Trial Design
2Treatment groups
Experimental Treatment
Group I: surgical patientsExperimental Treatment2 Interventions
Patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. The patient's PET/CT Brain scans may be acquired prior to surgery. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging.
Group II: non-surgical patientsExperimental Treatment2 Interventions
Before the patient's PET Brain scans patients will be i.v. injected with approximately 5 mCi (~3.4-6.7 nanomoles) of 89Zr-DFO-cRGDY-PEG-Cy5-C' dots (specific activity range 750.0 - 1450 mCi/ µmol) and undergo the microdosing study for purposes of collecting particle tracer kinetic and dosimetry data. All non-surgical and some surgical patients (at the discretion of the physician) will undergo PET brain imaging
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,939 Previous Clinical Trials
588,839 Total Patients Enrolled
Nelson Moss, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
106 Total Patients Enrolled
Media Library
Research Study Groups:
This trial has the following groups:- Group 1: non-surgical patients
- Group 2: surgical patients
Share this study with friends
Copy Link
Messenger